Gastrointestinal stromal tumours overexpress fatty acid synthase
- 31 March 2006
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 209 (3) , 369-375
Abstract
Fatty acid synthase (FASN), a key enzyme for de novo lipogenesis, is overexpressed in many malignant tumours and is associated with aggressive biological behaviour. FASN expression and its possible relationship with more aggressive behaviour in gastrointestinal stromal tumours (GISTs) have not been addressed to date. Here, FASN expression was assessed by immunohistochemistry in 60 primary GISTs (28 low/intermediate risk and 32 high risk) and seven metastatic GISTs. Sixteen smooth muscle gastrointestinal tumours were used as controls. FASN was overexpressed in 36 of 60 GISTs (60%): in 12 of 28 (42%) low/intermediate‐risk GISTs and in 24 of 32 (75%) high‐risk GISTs (p < 0.05). Two primary and seven metastatic GISTs and five GIST cell lines (GIST882, GIST430, GIST522, GIST62, and GIST48), analysed by western blot, showed variable FASN expression. Most metastatic samples expressed high levels of FASN protein. Additionally, seven of 60 GISTs showed a proliferation rate higher than 10% by Ki67 and all of them expressed FASN (p < 0.04). Finally, proliferation and apoptosis were investigated after FASN silencing in GIST882 cells, which displayed the highest FASN expression. siRNA‐mediated FASN knock‐down inhibited expression of the proliferation marker cyclin A, whereas no changes in p27 and cleaved PARP expression were seen. It is concluded that FASN is preferentially overexpressed in high‐risk and metastatic GISTs, and that its overexpression likely contributes to cell proliferation. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 43 references indexed in Scilit:
- Differential expression of connexin 43 in gastrointestinal stromal tumours of gastric and small intestinal originThe Journal of Pathology, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cellsOral Oncology, 2004
- Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal TumorsClinical Cancer Research, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal of Cancer, 2004
- Cloning, Expression, Characterization, and Interaction of Two Components of a Human Mitochondrial Fatty Acid SynthaseJournal of Biological Chemistry, 2003
- Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2002
- Androgen-Driven Prostate Epithelial Cell Proliferation and Differentiation in Vivo Involve the Regulation of p27Molecular Endocrinology, 2001
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998